MoonLake Immunotherapeutics
MLTX
$16.77
$0.040.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.44% | 49.78% | 48.05% | 46.29% | 35.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.11% | 111.17% | 156.21% | 179.87% | 164.38% |
| Operating Income | -71.11% | -111.17% | -156.21% | -179.87% | -164.38% |
| Income Before Tax | -89.91% | -158.70% | -208.07% | -222.80% | -175.01% |
| Income Tax Expenses | 116.67% | 41.61% | 71.47% | 138.10% | 199.05% |
| Earnings from Continuing Operations | -89.97% | -158.29% | -207.55% | -222.52% | -175.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 30.07% | 62.63% | -13.89% | -49.20% | -71.41% |
| Net Income | -91.13% | -160.62% | -221.44% | -256.99% | -230.31% |
| EBIT | -71.11% | -111.17% | -156.21% | -179.87% | -164.38% |
| EBITDA | -70.93% | -111.81% | -157.26% | -180.72% | -163.62% |
| EPS Basic | -86.40% | -157.74% | -208.47% | -206.97% | -147.85% |
| Normalized Basic EPS | -87.06% | -159.66% | -218.89% | -231.54% | -185.79% |
| EPS Diluted | -86.40% | -157.74% | -208.47% | -206.97% | -147.85% |
| Normalized Diluted EPS | -87.06% | -159.66% | -218.89% | -231.54% | -185.79% |
| Average Basic Shares Outstanding | 2.54% | 1.87% | 5.67% | 14.69% | 28.17% |
| Average Diluted Shares Outstanding | 2.54% | 1.87% | 5.67% | 14.69% | 28.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |